(3S,4R)-1-(Tert-Butoxycarbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid

Balancing Boc-Labile tert-Butyl Ester Hydrolysis During Solid-Phase Peptide Assembly

In Boc-strategy solid-phase peptide synthesis (SPPS) targeting macrocyclic heptapeptide Factor XIa inhibitors, the incorporation of (3S,4R)-1-(tert-butoxycarbonyl)-4-ethylpyrrolidine-3-carboxylic acid introduces a process conflict between the acidic conditions required for N^α-Boc removal and the sensitivity of the ethyl-substituted pyrrolidine carboxylic acid moiety to tert-butyl ester hydrolysis. When this building block is anchored to a phenylacetamidomethyl (PAM) resin with a loading of 0.68 mmol/g and a substitution variability below ±3%, the activation sequence must be executed using 1.5–2.0 equivalents of pre-mixed HBTU/HOBt (0.4 M in N-methylpyrrolidone) relative to free amine sites, with a coupling time truncated to 22 minutes at a jacket-controlled temperature of 18 ± 1 °C. Extended exposure beyond 30 minutes under the standard HBTU regimen triggers a measurable drift in diastereomeric purity: chiral HPLC analysis (Chiralpak IA-3, hexane/ethanol/trifluoroacetic acid 85:15:0.1) documents an increase in the cis-configured (3S,4S) epimer from <0.3% to 3.8% when the reaction mass is allowed to stand for 45 minutes at room temperature. Production-scale equipment—typically a 200 L rotary tilted solid-phase reactor with sintered PTFE filters of 20 µm porosity—requires a nitrogen overlay at 0.3 bar to suppress moisture ingress, since relative humidity above 55% promotes deblocking of the Boc group even before the scheduled TFA treatment. The N^α-deprotection itself is performed with 50% trifluoroacetic acid in dichloromethane containing 2% triisopropylsilane as a carbocation scavenger, with a residence time of exactly 6 minutes per cycle; departs from this narrow window cause progressive cleavage of the acid-labile PAM linker and loss of the growing chain into the filtrate, reducing overall isolated peptide yield by 12–18% per resin volume. Compliance with ICH Q3C (residual solvent limits) and USP <621> chromatographic system suitability is enforced through in-process LC-MS monitoring of the trifluoroacetyl adduct that forms when residual TFA is not adequately removed by post-cleavage DMF washes. The terminal product emerging from this assembly line is a crude, side-chain-protected heptapeptide containing a single (4R)-4-ethylproline residue at position 3, which is subsequently subjected to HF cleavage at 0 °C for 60 minutes in the presence of p-cresol and p-thiocresol scavengers to yield the disulfide-bridged macrocyclic Factor XIa antagonist currently evaluated in phase I trials for thrombosis prevention.

In the production of a phase II JAK2 V617F-selective inhibitor characterized by a pyrrolidine-fused tricyclic core, the (3S,4R)-1-(tert-butoxycarbonyl)-4-ethylpyrrolidine-3-carboxylic acid intermediate is introduced via a mixed carbonic anhydride activation protocol that demands exceptionally stringent temperature and stoichiometric control to preserve the chiral center at C3. The manufacturing procedure, conducted in a 500 L glass-lined reactor equipped with a pitched-blade turbine agitator rotating at 85–95 rpm, initiates with the dissolution of 1.05–1.08 molar equivalents of the Boc-protected pyrrolidine acid in anhydrous tetrahydrofuran (water content <0.01% by Karl Fischer) and the dropwise addition of isobutyl chloroformate at an internal temperature held between -12°C and -8°C through a jacketed brine circulator. After 15 minutes of anhydride formation, a pre-cooled solution of the amine fragment (1.00 eq, corresponding to a des-methyl quinazoline intermediate) is transferred via a jacketed line, and the coupling is continued for 45 minutes with a controlled warm-up to 2°C. Sampled aliquots are immediately quenched into an acidic quenching medium and analyzed by a validated chiral HPLC method (Column: Chiralpak AD-H, 250 × 4.6 mm; mobile phase: n-hexane/isopropanol/trifluoroacetic acid 80:20:0.1 at 1.0 mL/min) to verify that the (S)-epimer at the pyrrolidine 3-position remains below 0.5% area; excursions above this threshold trigger a batch rejection, as the resultant diastereomer cannot be removed by downstream crystallization and causes off-target JAK3 inhibition at picomolar levels. The post-reaction workup entails a bicarbonate wash to destroy excess mixed anhydride, followed by solvent exchange to ethyl acetate and a controlled pH 6.8–7.2 brine wash, since alkaline conditions above pH 8.5 accelerate intramolecular lactamization between the ethyl-bearing carbon and the liberated pyrrolidine nitrogen if premature Boc-deprotection occurs. The terminal product of this reaction sequence is the penultimate ester intermediate, which is telescoped into a hydrogenolysis/deprotection cascade under 3.5 bar hydrogen with 10% palladium-on-carbon (JM type 487) in methanol/tetrahydrofuran to deliver the free pyrrolidine kinase inhibitor base, ultimately formulated as a besylate salt for oral solid dosage development. Raw material specifications for the Boc-ethylpyrrolidine acid in this application require a certificate of analysis demonstrating enantiomeric excess not less than 99.5% by chiral SFC, residual palladium below 3 ppm (since the acid itself is prepared via asymmetric hydrogenation using a Ru-BINAP catalyst that leaves trace metal carryover), and absence of the des-ethyl analog—a contaminant that would propagate through the synthesis and create a difficult-to-remove byproduct co-eluting with the active pharmaceutical ingredient on reversed-phase preparative chromatography.

What Limits Turnover Number in 4-Alkylproline Organocatalysis Under Aqueous Conditions?

When the (3S,4R)-Boc-protected form is deprotected using 4 M hydrogen chloride in 1,4-dioxane at ambient temperature for 3 hours to yield (3S,4R)-4-ethylpyrrolidine-3-carboxylic acid hydrochloride, the resulting free amino acid functions as an enantioselective organocatalyst in direct asymmetric aldol condensations between cyclic ketones and electron-deficient aromatic aldehydes. The catalyst loading is typically set at 10 mol% relative to the aldehyde donor—a deliberate compromise, because raising this concentration to 20 mol% does increase the initial turnover frequency (TOF from 1.8 h⁻¹ to 2.3 h⁻¹) but concomitantly accelerates catalyst deactivation through irreversible iminium ion hydrolysis promoted by the water generated during the reaction. Operation in a biphasic cyclopentyl methyl ether/water (5:1 v/v) medium with 0.5 equivalent of benzoic acid as a co-catalyst shifts the equilibrium toward the enamine-intermediate, yet the turnover number plateaus at 28 ± 2 cycles under these conditions. Process intensification experiments conducted in a Corning Advanced-Flow reactor (G1 silicon carbide module, internal volume 8.2 mL) with a residence time of 27 minutes and a temperature of 22 °C enable a TON of 38, but only when a 0.22 µm inline filter is positioned upstream of the reactor to remove the hydrochloride salt precipitated during neutralization, preventing fouling of the micro-channels. From a regulatory standpoint, the deprotected catalyst destined for small-scale GMP-like research deliveries must be released under ISO 9001:2015 §8.6 control with residual dioxane not exceeding 380 ppm (per ICH Q3C Class 2 solvent limits) and benzene—a potential degradation product from dioxane—below 2 ppm, quantified by headspace GC-FID using a DB-624 column (30 m × 0.32 mm, 1.8 µm film). The terminal product of this downstream segment is the hydrochloride salt of (3S,4R)-4-ethylpyrrolidine-3-carboxylic acid, a non-hygroscopic white crystalline solid with a melting endotherm onset at 199 °C by differential scanning calorimetry, which serves as the immediate catalyst precursor for kilogram-scale research deliveries. It is incompatible with sulfonic acid co-catalysts such as p-toluenesulfonic acid monohydrate due to rapid esterification at the 3-carboxyl group, which generates an inactive pyrrolidinium tosylate ester with 15% conversion within 2 hours at room temperature in dichloromethane.

For the construction of cereblon (CRBN)-recruiting proteolysis-targeting chimeras directed against mutant EGFR, the (3S,4R) stereoisomer of 1-(tert-butoxycarbonyl)-4-ethylpyrrolidine-3-carboxylic acid is deployed as a conformationally restricted linker building block that positions the terminal pomalidomide warhead at a dihedral angle of 58° relative to the exit vector of the target-binding moiety, a geometry correlated with enhanced ternary complex formation (K_d decreased from 450 nM to 83 nM measured by SPR on a Biacore T200). The linker coupling to a 4-(aminomethyl)benzamide ligand fragment proceeds using 1.0 eq of the pyrrolidine acid activated with EDCI·HCl (1.1 eq) and OxymaPure (1.1 eq) in dimethylformamide containing 0.5% v/v triethylamine to scavenge hydrogen chloride, at a reaction concentration of 0.15 M. The addition sequence is critical: pre-activation of the carboxylate for 8 minutes at 0 °C before introducing the amine minimizes α-epimerization that would otherwise generate 1.2% of the undesired (R)-configured diastereomer detectable only by supercritical fluid chromatography with a Chiralcel OZ-3 column. The manufacturing lab-scale protocol, performed in a 20 L jacketed reactor vessel under a dry nitrogen sweep, includes an in-process check by UPLC-TOFMS (Acquity BEH C18 1.7 µm, 2.1 × 50 mm column) after 45 minutes: the target peptide-like conjugate must constitute ≥ 97.0% of the total ion current chromatogram, and the unreacted pyrrolidine acid must fall below 3.0% before transfer to the aqueous workup. Extraction proceeds with ethyl acetate at pH 5.0 (adjusted with 0.5 M citric acid) to partition the Boc-protected intermediate into the organic phase while retaining polar pomalidomide-based impurities in the aqueous layer. Compliance with REACH and the ISO/IEC 17025 traceability framework demands that each batch of the final PROTAC precursor—shipped as a lyophilized solid with acetic acid content below 0.05%—be accompanied by a statement of enantiomeric purity measured against a racemic reference standard, with a reporting limit of 0.1% for the undesired antipode, and a declaration of absence of the des-Boc fragment formed through thermal decomposition during drying, which is monitored by modulated DSC at a heating rate of 2 °C/min to detect the characteristic endotherm at 167 °C associated with the byproduct.

Resolving Atropisomer Formation in Trifunctionalized Delivery Conjugates

A specialized but commercially significant downstream channel involves the synthesis of triantennary N-acetylgalactosamine (GalNAc) conjugates for hepatocyte-targeted antisense oligonucleotide delivery, where the (3S,4R)-1-(tert-butoxycarbonyl)-4-ethylpyrrolidine-3-carboxylic acid provides a link between the clustered GalNAc ligand and a pH-sensitive cleavable spacer. The addition ratio in this lysine-based branching architecture is strictly stoichiometric: 1.00 equivalent of the amino-acid intermediate is coupled to a trivalent lysine core using propylphosphonic anhydride (T3P, 50% w/w in ethyl acetate, 1.3 eq) and N-methylmorpholine (2.5 eq) dissolved in isopropyl acetate at 0–5 °C. The process is compromised by atropisomer formation if the coupling temperature exceeds 12 °C; the restricted rotation around the newly formed amide bonds linking the pyrrolidine C3 carboxyl to the lysine ε-amino groups yields a mixture of slowly interconverting conformers, with the undesired rotamer exhibiting a 2.3-minute longer retention time on a C18 column (Kinetex EVO, 5 µm, 150 × 4.6 mm) and significantly reduced affinity for the asialoglycoprotein receptor (ASGPR) in a surface plasmon resonance binding assay. Production on pilot scale in a 100 L cylindrical reactor with a retreat-curve impeller at 115 rpm utilizes a pre-cooled dosing line to introduce the T3P solution over 35 minutes, and the reaction mixture is held for an additional 4 hours while the temperature is gradually raised to 22 °C. Spectroscopic monitoring via inline ReactIR with a diamond ATR probe tracks the disappearance of the carboxylic acid carbonyl stretch at 1708 cm⁻¹, and coupling is deemed complete when the signal intensity falls to baseline. The final terminal product—a triply branched, Boc-protected pyrrolidine-GalNAc triantennary ligand—is isolated by precipitation from methyl tert-butyl ether and dried under vacuum at 30 °C for 18 hours. The batch certification against ANSI/ESD S20.20 for disposal of electrostatically charged fine powder during drying and ICH Q6B §2.2.3 for peptide-like oligonucleotide conjugates requires documentation of residual T3P-derived phosphorus (ICP-OES detection limit 5 ppm), residual N-methylmorpholine (<50 ppm by ion chromatography), and a diastereomeric purity of ≥ 98.0% for the major atropisomer defined by the (3S,4R) configuration. Incompatibility with prolonged exposure to silanol-based normal-phase chromatography media is a known limitation; preparative-scale purification instead relies on low-temperature crystallization from isopropanol/water (3:1 v/v) seeded with 0.1 wt% authentic standard to direct the formation of the desired polymorph, as the alternative needle-like polymorph shows 30% lower dissolution rate and causes inconsistent coupling in the subsequent oligonucleotide attachment step on a DNA synthesizer running at a 1 mmol synthesis scale.